KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EBITDA (2016 - 2025)

Historic EBITDA for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to -$862000.0.

  • TherapeuticsMD's EBITDA rose 2398.59% to -$862000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year increase of 7094.82%. This contributed to the annual value of -$4.8 million for FY2024, which is 5368.75% up from last year.
  • Latest data reveals that TherapeuticsMD reported EBITDA of -$862000.0 as of Q3 2025, which was up 2398.59% from -$695000.0 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's EBITDA registered a high of $112.3 million during Q2 2022, and its lowest value of -$49.0 million during Q1 2022.
  • In the last 5 years, TherapeuticsMD's EBITDA had a median value of -$2.4 million in 2023 and averaged -$4.1 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 36324.91% in 2022, then plummeted by 10215.0% in 2023.
  • Quarter analysis of 5 years shows TherapeuticsMD's EBITDA stood at -$43.0 million in 2021, then soared by 280.87% to $77.7 million in 2022, then crashed by 101.14% to -$883000.0 in 2023, then skyrocketed by 179.28% to $700000.0 in 2024, then plummeted by 223.14% to -$862000.0 in 2025.
  • Its EBITDA was -$862000.0 in Q3 2025, compared to -$695000.0 in Q2 2025 and -$871000.0 in Q1 2025.